Evidence map›Paper›PMID 42110338›Full record

ArticleBiochemistry and biophysics reports2026

Clinicopathological significance of 5'-3' exoribonuclease 2 expression in small cell lung cancer tissues.

Rui Lin, Feng Chen, Wei Zhang, Zhi-Su Liu, Guo-Sheng Li, Xiao-Song Chen, Han He, Dong-Ming Li, Rong-Quan He, Gang Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rui LinDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Feng ChenDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Wei ZhangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Zhi-Su LiuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Guo-Sheng LiDepartment of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Xiao-Song ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Han HeDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Dong-Ming LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Rong-Quan HeDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Wan-Ying HuangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy. Overall survival in SCLC patients remains poor, and there is a lack of treatment options after the failure of first-line therapy. 5'-3' exoribonuclease 2 (XRN2) is associated with tumor progression. However, its mechanism in SCLC remains unclear. In this study, we collected and analyzed the expression data for XRN2 mRNA in SCLC and non-cancer lung tissues, as well as pan-cancer and non-cancer tissues from high-throughput datasets and identified XRN2 expression was significantly correlated with the prognosis of SCLC patients. Gene Ontology analysis indicated that XRN2 may promote tumor cell growth and development through biological processes. XRN2 performed better at distinguishing between the control group and samples of many tumors. Based on the TIMER and ESTIMATE algorithm analyses, this study revealed that XRN2 may act as a stimulator of immune responses in many tumors.Together,XRN2 overexpression may be associated with SCLC cell proliferation, migration, and invasion. High XRN2 expression is related to poor prognosis in SCLC and several other cancer types. XRN2 may also stimulate immune responses in many tumors.

Indexed as

Immune microenvironmentPan-cancerPrognosisSmall cell lung cancerTarget geneXRN2

Identifiers

PMID42110338
PMCPMC13157100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.